SBH
MDGL icon

Segall Bryant & Hamill’s Madrigal Pharmaceuticals MDGL Stock Holding History

Segall Bryant & Hamill’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4M Buy
32,444
+574
+2% +$294K 0.21% 176
2026
Q1 		$16.7M Sell
31,870
-1,650
-5% -$788K 0.24% 157
2025
Q4 		$19.5M Buy
33,520
+11,030
+49% +$5.63M 0.26% 134
2025
Q3 		$10.3M Buy
+22,490
New +$8.39M 0.14% 232

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Segall Bryant & Hamill's MDGL Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Madrigal Pharmaceuticals (MDGL) stake by 1.8% in Q2 2026, buying an estimated $294K and bringing the position to 32,444 shares worth $17.4M. The position accounts for 0.21% of the portfolio, ranked #176.

Segall Bryant & Hamill first reported a position in MDGL in Q3 2025 and has held it in 4 quarters since. The position peaked at $19.5M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Segall Bryant & Hamill held 32,444 shares of Madrigal Pharmaceuticals worth $17.4M as of Q2 2026.
  • Segall Bryant & Hamill bought 574 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $294K.
  • Madrigal Pharmaceuticals made up 0.21% of Segall Bryant & Hamill's portfolio in Q2 2026, its #176 holding.
  • Segall Bryant & Hamill first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Segall Bryant & Hamill's Madrigal Pharmaceuticals position peaked at $19.5M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.